Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

141. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 Full Text available with Trip Pro

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date (...) range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018 David Brieger, John Amerena, John R Attia, Beata Bajorek, Kim H Chan

2018 MJA Clinical Guidelines

142. Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review

Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review | CADTH.ca Find the information you need Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart Failure: A Rapid Qualitative Review Patients’ Experiences with Cardiac Monitors for Stroke, Atrial Fibrillation, and Heart (...) Failure: A Rapid Qualitative Review Last updated: September 17, 2018 Project Number: RC1019-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question How do patients experience, make decisions around, and live with outpatient cardiac monitors for the diagnosis of stroke, atrial fibrillation, and/or heart failure? Key Message The onset of cardiac monitor use accompanies many life changes and new personal responsibilities. For some

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

143. Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. (Abstract)

Efficacy and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation and a History of Cancer: Observations from ROCKET AF. The management of anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is challenging due to increased thrombotic and bleeding risks. We sought to determine the safety and efficacy of rivaroxaban in patients with AF and a history of cancer.ROCKET AF randomized 14,264 patients with AF to rivaroxaban or warfarin

2018 European heart journal. Quality of care & clinical outcomes Controlled trial quality: predicted high

144. New-onset atrial fibrillation

New-onset atrial fibrillation New-onset atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  New-onset atrial fibrillation Last reviewed: February 2019 Last updated: June 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age and affects almost 5% of the population older than 69 years of age. Causes significant morbidity and mortality including (...) palpitations, dyspnoea, angina, dizziness or syncope, and features of congestive heart failure (CHF), tachycardia-induced cardiomyopathy, stroke, and death. ECG shows absent P waves, presence of fibrillatory waves, and irregularly irregular QRS complexes. Most patients presenting with new-onset or 'acute' atrial fibrillation (AF) do not require immediate cardioversion. Most patients will require medical therapy to control ventricular rate. Patients who develop haemodynamic compromise should have immediate

2018 BMJ Best Practice

145. Chronic atrial fibrillation

Chronic atrial fibrillation Chronic atrial fibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic atrial fibrillation Last reviewed: February 2019 Last updated: October 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age. Patients frequently have co-existing cardiac or non-cardiac conditions, such as hypertension, coronary artery disease (...) , pacemakers, and ablation of the atrioventricular node need to be weighed based on multiple clinical factors to optimise patient outcome. Definition Atrial fibrillation (AF) is a supraventricular tachyarrhythmia. It is characterised by uncoordinated atrial activity on the surface ECG, with fibrillatory waves of varying shapes, amplitudes, and timing associated with an irregularly irregular ventricular response when atrioventricular (AV) conduction is intact. [Figure caption and citation for the preceding

2018 BMJ Best Practice

146. Less dementia with oral anticoagulation in atrial fibrillation Full Text available with Trip Pro

Less dementia with oral anticoagulation in atrial fibrillation The association between atrial fibrillation (AF) and dementia is well documented, but it is not clear if oral anticoagulant treatment offers protection. The aim of the study is therefore to compare the incidence of new dementia in patients with AF with and without oral anticoagulants, and to explore if there is a difference between novel anticoagulants and warfarin in this respect.Retrospective registry study of all patients

2018 EvidenceUpdates

147. Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults)

Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) NHS England » Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation (adults) Search Search Menu Clinical Commissioning Policy: Left Atrial Appendage Occlusion for patients with atrial fibrillation and relative (...) or absolute contraindications to anticoagulation (adults) Document first published: 9 July 2018 Page updated: 9 July 2018 Topic: , Publication type: This policy document outlines the arrangements for funding of treatment for patients with atrial fibrillation and relative or absolute contraindications to anticoagulation. Document PDF 572 KB 28 pages

2018 NHS England

148. NOACs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

NOACs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation '); } else { document.write(' '); } ACE | Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation Search > > Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation - Novel oral anticoagulants (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial (...) fibrillation First published on 3 May 2017 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: Rivaroxaban 15 mg and 20 mg tablets, and apixaban 2.5 mg and 5 mg tablets for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and : CHA 2 DS 2 -VASc score of 1 or more for men; and CHA 2 DS 2 -VASc score of 2 or more for women. Rivaroxaban or apixaban should not be used in patients with valvular AF (especially rheumatic mitral

2018 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

149. Atrial Fibrillation: Screening With Electrocardiography

Atrial Fibrillation: Screening With Electrocardiography Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for atrial fibrillation with electrocardiography (ECG). See the Clinical Considerations section (...) for suggestions for practice regarding the I statement. I View the Clinical Summary in Population Older adults Recommendation No recommendation. Grade: I (insufficient evidence) Risk Assessment Atrial fibrillation is strongly associated with older age and obesity. Other risk factors include high blood pressure, diabetes, heart failure, prior cardiothoracic surgery, current smoking, prior stroke, sleep apnea, alcohol and drug use, and hyperthyroidism. Screening Tests The USPSTF found inadequate evidence

2018 U.S. Preventive Services Task Force

150. Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study Full Text available with Trip Pro

Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study Atrial fibrillation (AF) is associated with a high risk of thromboembolic stroke and oral anticoagulation therapy (OAT) is able to reduce the rate of ischemic events. Nevertheless, the actual benefit of prolonged OAT after successful radiofrequency catheter ablation (RFCA) is not clear yet.Scientific investigations were assumed suitable if they assessed

2017 Frontiers in cardiovascular medicine

151. Ablation of Atrial Fibrillation in Patients with Congenital Heart Disease Full Text available with Trip Pro

Ablation of Atrial Fibrillation in Patients with Congenital Heart Disease With improved surgical techniques and medical management for patients with congenital heart diseases, more patients are living longer and well into adulthood. This improved survival comes with a price of increased morbidity, mainly secondary to increased risk of tachyarrhythmias. One of the major arrhythmias commonly encountered in this subset of cardiac patients is AF. Similar to the general population, the risk of AF (...) . This review will shed light on the procedural techniques, success rates and complications of AF catheter ablation in patients with different types of CHD, including atrial septal defects, tetralogy of Fallot, persistent left superior vena cava, heterotaxy syndrome and atrial isomerism, and Ebstein anomaly.

2017 Arrhythmia & electrophysiology review

152. Ablation of Atrial Fibrillation Drivers Full Text available with Trip Pro

Ablation of Atrial Fibrillation Drivers Pulmonary vein isolation (PVI) is central to ablation approaches for atrial fibrillation (AF), yet many patients still have arrhythmia recurrence after one or more procedures, despite evolving technologies for PVI. Ablation of localised AF drivers, which lie outside the pulmonary veins in many patients, is a practical approach that has been shown to improve success by many groups. Such localised drivers lie in atrial regions shown mechanistically

2017 Arrhythmia & electrophysiology review

153. Management of Complications in Anticoagulated Patients with Atrial Fibrillation Full Text available with Trip Pro

Management of Complications in Anticoagulated Patients with Atrial Fibrillation Oral anticoagulation is mandatory for patients at high risk of thromboembolism, but the risk of bleeding should also be taken into account. Direct oral anticoagulants are now recommended for non-valvular AF as a potential alternative to warfarin. In this article we discuss methods to assess the anticoagulant effect of these agents, specific and general antidotes, and management of complications such as embolic

2017 Arrhythmia & electrophysiology review

154. Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy? Full Text available with Trip Pro

Optimum Risk Assessment for Stroke in Atrial Fibrillation: Should We Hold the Status Quo or Consider Magnitude Synergism and Left Atrial Appendage Anatomy? Thromboembolic stroke and systemic embolism are generally agreed to be the major morbidity/mortality concerns for patients with AF. However, the risk of thromboembolism is not the same for all AF patients. Both AF and comorbidities must interact synergistically to create the risk for thromboembolism. But, is the synergism dichotomous - AF (...) present or absent, comorbid disorder present or absent - or does synergism have magnitude, depending on the number and severity of the associated disorders and the amount of time one is in AF? This review discusses the current risk-score contributors and options for assessing risk of thromboembolism in AF patients, and what their combined roles might be. Also covered is the consideration of left atrial appendage anatomy in this context.

2017 Arrhythmia & electrophysiology review

155. One-stage Approach for Hybrid Atrial Fibrillation Treatment Full Text available with Trip Pro

One-stage Approach for Hybrid Atrial Fibrillation Treatment The one-stage approach for hybrid atrial fibrillation involves the simultaneous and close cooperation of different medical specialties. This review attempts to describe its challenging issues, exposing a plan to balance thrombotic risk and bleeding risk. It describes the combined surgical-electrophysiological procedure. Specific topics, involving hemodynamic, fluid and respiratory management during surgery are considered, and problems

2017 Arrhythmia & electrophysiology review

156. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation Full Text available with Trip Pro

Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation We investigated the incidence of nonembolic adverse events in 2 cohorts of patients with atrial fibrillation (AF) and validated the 2MACE score ([metabolic syndrome, age ≥75] [doubled]; [myocardial infarction or revascularization, congestive heart failure {HF}, and stroke, transient ischemic attack or thromboembolism]) as predictor of major adverse cardiovascular events (MACEs). We

2017 EvidenceUpdates

157. CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study Full Text available with Trip Pro

CHA2DS2-VASc Score for Identifying Truly Low-Risk Atrial Fibrillation for Stroke: A Korean Nationwide Cohort Study As the threshold of stroke risk for initiating oral anticoagulants is lowered after the introduction of the nonvitamin K antagonist oral anticoagulants, the focus of stroke prevention in patients with nonvalvular atrial fibrillation has shifted away from predicting high-risk patients toward initially identifying patients with a truly low risk of ischemic stroke, who do not need (...) antithrombotic therapy. We tested the predictive ability of the congestive heart failure, hypertension, age ≥75, diabetes mellitus, prior stroke or transient ischemic attack (doubled; CHADS2), congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65 to 74, female (CHA2DS2-VASc), and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) risk stratification schemes in oral anticoagulants naive patients

2017 EvidenceUpdates

158. Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke

Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke 1 Public Summary Document Application No. 1443 – Implantable loop recorders for diagnosis of atrial fibrillation in cryptogenic stroke Applicant: Medtronic Australasia Pty Ltd Date of MSAC consideration: MSAC 69 th Meeting, 6-7 April 2017 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application An application requesting Medicare (...) Benefits Schedule (MBS) listing for the insertion of implantable loop recorders (ILR), and an investigation service of the inserted ILR, for the diagnosis of atrial fibrillation (AF) in patients with cryptogenic stroke or embolic stroke of undetermined source (CS/ESUS) was received from Medtronic Australasia Pty Ltd by the Department of Health (the Department). 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to the comparative safety, clinical

2017 Medical Services Advisory Committee

159. PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial Full Text available with Trip Pro

PulmOnary vein isolation With vs. without continued antiarrhythmic Drug trEatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial Catheter ablation is indicated in patients with symptomatic paroxysmal atrial fibrillation (AF) resistant to antiarrhythmic drug therapy (ADT). We investigated whether continued use of previously ineffective ADT beyond the post-ablation blanking period reduces recurrence of atrial tachyarrhythmia within the 1st (...) visits, Holter monitoring, and quality-of-life (QOL) questionnaires at 6 and 12 months post-procedure. Analysis of the primary endpoint (any documented atrial tachyarrhythmia lasting >30 s) was performed according to the modified intention-to-treat principle. Secondary endpoints included repeat ablation, unscheduled visits, and QOL score. Baseline clinical characteristics and initial ablation procedure characteristics were comparable between both groups. Three patients were lost to follow-up in each

2017 EvidenceUpdates

160. Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: Results of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study Full Text available with Trip Pro

Quality of life improves after thoracoscopic surgical ablation of advanced atrial fibrillation: Results of the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (AFACT) study We evaluated health-related quality of life at 12 months after thoracoscopic surgical ablation in patients enrolled in the Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery study. The Atrial Fibrillation Ablation and Autonomic Modulation via Thoracoscopic Surgery (...) study assessed the efficacy and safety of ganglion plexus ablation in patients with symptomatic advanced atrial fibrillation undergoing thoracoscopic surgical ablation.Patients (n = 240) underwent thoracoscopic pulmonary vein isolation with additional ablation lines in patients with persistent atrial fibrillation. Subjects were randomized to additional ganglion plexus ablation or control. Short Form 36 quality of life questionnaires were collected at baseline and at 6 and 12 months of follow-up.A

2017 EvidenceUpdates